Tag: paxil

Drug safety advocate David Carmichael joins us to discuss his upcoming antidepressant safety tour and the importance of fully informed consent when prescribing SSRI antidepressants.

“My life was very, very good.” That’s how Michael sums up how things were for him—prior to his suffering from devastating withdrawal effects after discontinuing GlaxoSmithKline’s blockbuster drug Paxil.

Jay Amsterdam, who first blew the whistle on corrupt research practices in a study conducted by GlaxoSmithKline (GSK) eight years ago, has now submitted...

Formed to help and support those in need of help coming off of the SSRI (selective serotonin reuptake inhibitor) known by the name of PAXIL, SEROXAT or generically as PAROXETINE.

Today on the MIA podcast we talk to Bobby Fiddaman about his experiences of the mental health system, his research and campaigning over the years and his relationships with the UK and US pharmaceutical regulatory bodies.

On this episode of the MIA Radio podcast, we present part one of an interview with Dr. Peter Breggin about his career, his views on psychiatry and recent developments with the Michelle Carter trial in which he testified as an expert medical witness.

Jim Gottstein, president and founder of the organisation Law Project for Psychiatric Rights, talks about his own experiences with the psychiatric system, patient rights in mental healthcare and the recent trial between Wendy Dolin and the UK Pharmaceutical manufacturer GlaxoSmithKline.

The jury was out for days. And when they came back it became clear they were wrestling with the issue of who to blame. This was like playing Go, where it can look like the black counters on the board have white encircled until white puts down one more piece and all of a sudden it wins.

Finally, faced with the twenty known and two possible suicides on Paxil during clinical trials, Dr. Kraus reluctantly conceded that 80% of the victims were over thirty. Whatever they had told the FDA, the risks of Paxil could not be confined to adolescents — and GSK knew it.

In July of 2010, Stewart Dolin, a partner at the mega law firm Reed Smith, jumped in front of a subway train in Chicago, apparently suffering from akathisia caused by paroxetine. His widow sued, and the jury found GSK negligent in not informing doctors of the suicide risk

Adults in the U.S. diagnosed with “serious mental illness” die on average 25 years earlier than others. This is not controversial, as establishment psychiatry and its critics agree. What is controversial is who is to blame?

Although the drug industry, our drug regulators and leading psychiatrists have done what they could to obscure these facts, it can no longer be doubted that antidepressants are dangerous and can cause suicide and homicide at any age.

The judicial system and the public are becoming increasingly aware of the hazards of psychiatric drugs, including their capacity to make people behave in ways that are harmful to themselves and others, and contrary to their past behavior and character.

Most doctors still affect surprise at the idea SSRIs might come with withdrawal problems. Regulators knew very clearly since 2002 about the problems, but have decided to leave any communication of these issues in company hands.

All the fuss about Study 329 centers on its 8-week acute phase. But this study had a 24-week Continuation Phase that has never been published. Until Now.

I have hopes for the field of psychiatry. I hope the field will redeem itself, and redeem its practitioners, because they do have clinical skill and the opportunity to learn more and grow. Many of them, I believe, were just taught bad science, influenced and infiltrated by Big Pharma.

I lost almost four years of my life, and I’ve not a doubt that it was due to those “life-saving” pills. To that end, they did work. At a time when I was doubled-over with depression, those four prescriptions kept me alive. But then they killed me slowly and brought me back as a stranger.

The assertion that the so-called antidepressants are being over-prescribed implies that there is a correct and appropriate level of prescribing and that depression is a chronic illness (just like diabetes). It has been an integral part of psychiatry's message that although depression might have been triggered by an external event, it is essentially an illness residing within the person's neurochemistry. The issue is not whether people should or shouldn't take pills. The issue is psychiatry pushing these dangerous serotonin-disruptive chemicals on people, under the pretense that they have an illness.

Here I was, 15 years old and already in a long-term treatment facility. I was, on paper: crazy! This entire time, all the adults in my life had been speaking for me. I never felt like I was any of the things they said, but I went along with it. What else could I have done? Every time I rebelled, it only confirmed to my mother what she thought of me.

When we set out to restore GSK’s misreported Study 329 of paroxetine for adolescent depression under the RIAT initiative, we had no idea of the magnitude of the task we were undertaking. After almost a year, we were relieved to finally complete a draft and submit it to the BMJ, who had earlier indicated an interest in publishing our restoration. But that was the beginning of another year of peer review that we believed went beyond enhancing our paper and became rather an interrogation of our honesty and integrity. Frankly, we were offended that our work was subject to such checks when papers submitted by pharmaceutical companies with fraud convictions are not.

He could have asked me if there was a specific event that had precipitated my suicide attempt. He could have asked if I had a history of trauma. He could have simply asked, “What happened?” “What are you feeling?” or “So what’s going on?” Nope. He chose to open our meeting with an accusatory remark about a make-believe eating disorder.

Psychiatry would long since have gone the way of phrenology and mesmerism but for the financial support it receives from the pharmaceutical industry. But the truth has a way of trickling out. Here are five recent stories that buck the psychiatry-friendly stance that has characterized the mainstream media for at least the past 50 years.

Reuters reports that GlaxoSmithKline has been fined $54.4 million by the UK for “market abuse in striking deals to delay the launch of cheap...

Wendy Dolin sued GSK after her husband committed suicide after taking a generic version of Paxil. The US District Court has declined GSK’s motions...

“Those who possess the data control the story.” In the wake of the reanalysis of the infamous Study 329, where scientific data claiming the antidepressant Paxil was safe and effective for teens was egregiously manipulated, researchers are pushing for open access to raw data. “The issue here, scientists argue, is that without independent confirmation, it becomes too easy to manipulate data.”